Yujiro S. Hata - 18 Feb 2025 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Reporting relationship
President and CEO, Director
Issuer ticker
IDYA
Reported as of
18 Feb 2025
Net transaction value
+$250,012
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
19 Feb 2025, 06:00:15 UTC
Prior SEC filing
16 May 2024
Next SEC filing
28 Feb 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Andres Ruiz Briseno, as Attorney-in-Fact for Yujiro Hata

Key filing fact

Yujiro S. Hata filed Form 4 for IDEAYA Biosciences, Inc. (IDYA) on 19 Feb 2025.

Key facts

  • This page summarizes Yujiro S. Hata's Form 4 filing for IDEAYA Biosciences, Inc. (IDYA).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 19 Feb 2025, 06:00.

Change

  • Previous filing in this sequence was filed on 16 May 2024.
  • Current net transaction value: +$250,012.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDYA transaction

Common Stock

Options Exercise

Transaction value
$250,012
Shares
+12,808
Change %
+1.9%
Price
$19.52
Shares after
690,695
Date
18 Feb 2025
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDYA transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
$0
Shares
-12,808
Change %
-6.6%
Price
$0.000000
Shares after
182,192
Date
18 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,808
Exercise price
$19.52
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option are fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .